NCT03733106

Brief Summary

The accuracy of standard two dimension digital mammography (2DDM) in breast cancer screening is limited because of superimposition of normal breast structures onto a two dimensional image. Mammography signs of breast cancer may be obscured, resulting in delay in the diagnosis of breast cancer. Conversely, superimposition of normal tissues may produce features on mammography which are suspicious for cancer and lead to recall for further tests. Digital breast tomosynthesis (DBT) is a new x ray mammography technique which provides three dimensional information to the film reader, overcoming many of the interpretation problems due to tissue superimposition. Studies of DBT + 2DDM in screening have shown increased cancer detection rates and lower false positive recall rates. There may be increased costs related to the technology and reading times. The aim of this study is to measure the impact and cost effectiveness of DBT + 2DDM in routine screening compared to standard 2DDM.100,000 women wil be recruited using NHS BSP screening sites. At each site, through a clinic randomization process, half of the participants will undergo standard screening with 2DDM (the control group) and half will undergo screening using DBT+2DDM.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for not_applicable breast-cancer

Timeline
Completed

Started Dec 2018

Longer than P75 for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 10, 2017

Completed
1.1 years until next milestone

First Posted

Study publicly available on registry

November 7, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

December 17, 2018

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

November 6, 2019

Status Verified

November 1, 2019

Enrollment Period

5.5 years

First QC Date

October 10, 2017

Last Update Submit

November 4, 2019

Conditions

Keywords

screeningtomosynthesis

Outcome Measures

Primary Outcomes (1)

  • To compare the cost effectiveness of breast cancer screening with digital breast tomosynthesis and 2DDM vs standard screening with 2DDM

    To compare the effectiveness of breast cancer screening with DBT and 2D mammography with standard 2D mammography screening by measuring the internal cancer rate in women undergoing DBT and 2D mammography VS the interval cancer rate in women undergoing standard 2D mammography. (Estimated interval cancer rates - intervention group 1.85/1000 screened; control group 2.85/1000 screened)

    outcome measures to be reported from 2-7 years following beginning of recruitment into the trial

Study Arms (2)

digital breast tomosynthesis

EXPERIMENTAL

Tomosynthesis and two dimension digital mammography

Diagnostic Test: digital breast tomosynthesis

control

ACTIVE COMPARATOR

standard two dimension digital mammography

Diagnostic Test: standard two dimension digital mammogram

Interventions

pseudo three dimension mammography

digital breast tomosynthesis

standard two dimension mammogram

control

Eligibility Criteria

Age50 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • women aged 50-70 years attending for routine breast cancer screening

You may not qualify if:

  • women aged 47-49 and 71-73 invited to participate in the age extension trial
  • women who are unable to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King's College Hospital NHS Foundation Trust

London, United Kingdom

RECRUITING

Related Publications (2)

  • J W Partridge G, Darker I, J James J, Satchithananda K, Sharma N, Valencia A, Teh W, Khan H, Muscat E, J Michell M, Chen Y. How long does it take to read a mammogram? Investigating the reading time of digital breast tomosynthesis and digital mammography. Eur J Radiol. 2024 Aug;177:111535. doi: 10.1016/j.ejrad.2024.111535. Epub 2024 May 29.

  • Partridge GJW, Taib AG, Phillips P, James JJ, Satchithananda K, Sharma N, Morel J, McAvinchey R, Valencia A, Teh W, Khan H, Muscat E, Michell MJ, Chen Y. Take a break: should breaks be enforced during digital breast tomosynthesis reading sessions? Eur Radiol. 2024 Feb;34(2):1388-1398. doi: 10.1007/s00330-023-10086-4. Epub 2023 Aug 17.

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Mammography

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

RadiographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Michael J Michell, FRCR

    King's College Hospital NHS Foundation Trust, London

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael J Michell, FRCR

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
participants blinded to type of screening scan
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: Prospective randomized controlled study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 10, 2017

First Posted

November 7, 2018

Study Start

December 17, 2018

Primary Completion

July 1, 2024

Study Completion

July 1, 2024

Last Updated

November 6, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

There is no plan to make individual participant data available to individuals outside the research team

Locations